Physician profile
Daniel B Pope
NPI 1891890265
$1,742.78
in general payments reported to CMS, 2019-2025
24 companies · $281 in 2025
The $281 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $133 · 2021: $479 · 2022: $121 · 2023: $198 · 2024: $211 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $268.75 | 2022-2025 | |
| Alcon Vision LLC | $228.85 | 2019-2025 | Rocklatan, Clareon, Clareon Panoptix Pro |
| Allergan, INC. | $204.06 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $188.10 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $96.13 | 2021 | |
| Dompe US, INC. | $72.91 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $71.61 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $59.63 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $57.59 | 2022-2023 | Vyzulta, Prolensa |
| Thea Pharma INC. | $55.84 | 2022-2023 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $54.96 | 2025 | Xdemvy |
| Akorn Operating Company LLC | $53.06 | 2021 | |
| Eyevance Pharmaceuticals LLC | $46.06 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $39.94 | 2021 | |
| Ocular Therapeutix, INC. | $39.53 | 2020-2025 | Dextenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36.26 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $35.02 | 2019-2023 | Tepezza |
| Omeros Corporation | $31.23 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.36 | 2021 | |
| Astellas Pharma US INC | $19.59 | 2024 | Izervay |
| Glaukos Corporation | $18.38 | 2019 | |
| Ivantis, INC | $18.03 | 2021 | |
| Rxsight INC | $14.51 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Sight Sciences, INC. | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.